Factors Related to Mortality in Patients with Fournier’s Gangrene or Necrotising Fasciitis; a 10-year Cross-Sectional Study
Archives of Academic Emergency Medicine,
Vol. 9 No. 1 (2021),
1 January 2021
,
Page e33
https://doi.org/10.22037/aaem.v9i1.1123
Abstract
Introduction: Fournier’s gangrene (FG) is a life-threatening disease, even with early diagnosis and administration of vigorous treatment, its mortality rate is high. This study aimed to evaluate the factors relate to mortality in patients with FG or necrotising fasciitis managed in a referral center.
Methods: This retrospective cross-sectional study was conducted on patients managed in a tertiary referral center, Tehran, Iran, from March 2009 to March 2019, with diagnosis of FG or necrotising fasciitis. The correlation between different demographic and clinical parameters with mortality was analysed and reported.
Results: 73 cases with the mean age of 59.1 ± 15.8 (range: 25 – 88) years were studied (87.7% male). 21 (28.8%) patients died. Escherichia coli (26 cases, 35.6%) was the most frequent microorganism in cultures. Non-survived cases had higher mean age (p = 0.01), higher frequency of hyperlipidaemia (p = 0.02), immunosuppression (p < 0.001), longer hospital stay (p=0.02), lower blood pressure (p=0.01), and lower platelet count (p=<0.001). Based on multivariate analysis, age (p = 0.015; Odds: 0.88 (0.79-0.97)), haematocrit level (p = 0.01; Odds: 1.27 (1.04-1.55)), platelet count (p = 0.03; Odds: 10.11 (1.14-89.35)), and immunosuppression (p = 0.01; Odds: 0.01 (0.0-0.54)) were independent related factors of mortality.
Conclusions: The rate of mortality due to FG and necrotizing fasciitis was 28.8%. Based on multivariate analysis, the independent related factors of mortality were older age, lower haematocrit level and platelet count, and presence of immunosuppression.
- Fournier’s Gangrene
- Severity of Illness Index
- Mortality
- Thrombocytopenia
How to Cite
References
Hsu J-M, Chen M, Weng C-H, Tseng J-S. Fournier's gangrene: Clinical characteristics in the elderly. International Journal of Gerontology. 2014;8(3):162-5.
Eke N. Fournier's gangrene: a review of 1726 cases. British Journal of Surgery. 2000;87(6):718-28.
Laor E, Palmer LS, Tolia BM, Reid RE, Winter HI. Outcome prediction in patients with Fournier's gangrene. The Journal of urology. 1995;154(1):89-92.
Spirnak JP, Resnick MI, Hampel N, Persky L. Fournier’s gangrene: report of 20 patients. The Journal of urology. 1984;131(2):289-91.
Medina Polo J, Tejido Sánchez A, De la Rosa Kehrmann F, Felip Santamaría N, Blanco Álvarez M, Leiva Galvis O. Gangrena de Fournier: estudio de los factores pronósticos en 90 pacientes. Actas urológicas españolas. 2008;32(10):1024-30.
Jeong HJ, Park SC, Seo IY, Rim JS. Prognostic factors in Fournier gangrene. International journal of urology. 2005;12(12):1041-4.
Luján Marco S, Budía A, Di Capua C, Broseta E, Cruz FJ. Evaluation of a severity score to predict the prognosis of Fournier’s gangrene. BJU international. 2010;106(3):373-6.
Corcoran A, Smaldone M, Gibbons E, Walsh T, Davies B. Validation of the Fournier's gangrene severity index in a large contemporary series. The Journal of urology. 2008;180(3):944-8.
Lin TY, Ou CH, Tzai TS, Tong YC, Chang CC, Cheng HL, et al. Validation and simplification of F ournier's gangrene severity index. International Journal of Urology. 2014;21(7):696-701.
Tuncel A, Aydin O, Tekdogan U, Nalcacioglu V, Capar Y, Atan A. Fournier’s gangrene: three years of experience with 20 patients and validity of the Fournier’s gangrene severity index score. European urology. 2006;50(4):838-43.
Hazrati E, Noorifard M, Afsahi M, Rohi A, Rafiei M. The relationship between lipid profile and CRP in severe sepsis with patient prognosis. Journal of Advanced Pharmacy Education & Research| Jan-Mar. 2018;8(1).
Martinelli G, Alessandrino E, Bernasconi P, Caldera D, Colombo A, Malcovati L, et al. Fournier’s gangrene: a clinical presentation of necrotizing fasciitis after bone marrow transplantation. Bone marrow transplantation. 1998;22(10):1023-6.
Kuo C, Wang W, Lee C, Liu C, Tseng H. Fournier's gangrene: ten-year experience in a medical center in northern Taiwan. Journal of Microbiology Immunology and Infection. 2007;40(6):500.
Yeniyol CO, Suelozgen T, Arslan M, Ayder AR. Fournier's gangrene: experience with 25 patients and use of Fournier's gangrene severity index score. Urology. 2004;64(2):218-22.
Tuncel A, Keten T, Aslan Y, Kayali M, Erkan A, Koseoglu E, et al. Comparison of different scoring systems for outcome prediction in patients with Fournier's gangrene: experience with 50 patients. Scandinavian journal of urology. 2014;48(4):393-9.
Saeidinia A, Keihanian F, Delavar SF, Keihanian F, Ranjbar A, Karkan MF. Lack of antibacterial activity of Ruta graveolens extracts against Enterococcus fecalis. Pak J Pharm Sci. 2016;29(4):1371-4.
Chawla SN, Gallop C, Mydlo JH. Fournier’s gangrene: an analysis of repeated surgical debridement. European urology. 2003;43(5):572-5.
Kabay S, Yucel M, Yaylak F, Algin MC, Hacioglu A, Kabay B, et al. The clinical features of Fournier’s gangrene and the predictivity of the Fournier’s Gangrene Severity Index on the outcomes. International urology and nephrology. 2008;40(4):997-1004.
Clayton M, Fowler JJ, Sharifi R, Pearl R. Causes, presentation and survival of fifty-seven patients with necrotizing fasciitis of the male genitalia. Surgery, gynecology & obstetrics. 1990;170(1):49-55.
Yeaman MR. The role of platelets in antimicrobial host defense. Platelets: Elsevier; 2019. p. 523-46.
Venkata C, Kashyap R, Farmer JC, Afessa B. Thrombocytopenia in adult patients with sepsis: incidence, risk factors, and its association with clinical outcome. Journal of intensive care. 2013;1(1):9.
Stephan F, Montblanc J, Cheffi A, Bonnet F. Thrombocytopenia in critically ill surgical patients: a case-control study evaluating attributable mortality and transfusion requirements. Critical Care. 1999;3(6):151.
- Abstract Viewed: 1020 times
- pdf Downloaded: 476 times
